Dennis Ding
Stock Analyst at Jefferies
(4.14)
# 1,606
Out of 4,698 analysts
90
Total ratings
59%
Success rate
12.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintained: Buy | $40 | $36.36 | +10.01% | 6 | Sep 3, 2026 | |
| KARD Kardigan | Initiated Coverage: Buy | $40 | $20.85 | +91.85% | 1 | Jul 13, 2026 | |
| TSX: APTX Apotex Health Corp. | Initiated Coverage: Buy | $40.00 | $33.63 | +18.94% | 1 | Jul 6, 2026 | |
| ARDX Ardelyx | Maintained: Buy | $15 | $3.78 | +296.83% | 7 | Jun 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $125 | $102.74 | +21.67% | 10 | Jun 15, 2026 | |
| SGP SpyGlass Pharma | Maintained: Buy | $62 | $28.94 | +114.24% | 4 | May 19, 2026 | |
| AMPH Amphastar Pharmaceuticals | Downgraded: Hold | $22 | $23.18 | -5.09% | 1 | Apr 21, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $40 | $10.75 | +272.09% | 1 | Mar 19, 2026 | |
| ROIV Roivant Sciences | Maintained: Buy | $18 → $30 | $34.93 | -14.11% | 16 | Feb 9, 2026 | |
| ABUS Arbutus Biopharma | Maintained: Buy | $7 | $5.15 | +35.92% | 4 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $15 → $26 | $28.21 | n/a | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $34.94 | n/a | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $45 | $25.40 | n/a | 14 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $20 → $18 | $39.25 | n/a | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $2.50 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $35 | $36.60 | n/a | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $8 → $6 | $3.63 | n/a | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $1 | $2.64 | n/a | 2 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,275 → $70 | $19.90 | n/a | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $1.91 | n/a | 3 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $35 → $22 | $111.62 | n/a | 4 | Feb 14, 2023 |
Teva Pharmaceutical Industries
Sep 3, 2026
Maintained: Buy
Price Target: $40
Current: $36.36
Upside: +10.01%
Kardigan
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $20.85
Upside: +91.85%
Apotex Health Corp.
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $40.00
Current: $33.63
Upside: +18.94%
Ardelyx
Jun 26, 2026
Maintained: Buy
Price Target: $15
Current: $3.78
Upside: +296.83%
Rhythm Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $125
Current: $102.74
Upside: +21.67%
SpyGlass Pharma
May 19, 2026
Maintained: Buy
Price Target: $62
Current: $28.94
Upside: +114.24%
Amphastar Pharmaceuticals
Apr 21, 2026
Downgraded: Hold
Price Target: $22
Current: $23.18
Upside: -5.09%
Olema Pharmaceuticals
Mar 19, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $10.75
Upside: +272.09%
Roivant Sciences
Feb 9, 2026
Maintained: Buy
Price Target: $18 → $30
Current: $34.93
Upside: -14.11%
Arbutus Biopharma
Dec 11, 2025
Maintained: Buy
Price Target: $7
Current: $5.15
Upside: +35.92%
Sep 3, 2025
Maintained: Hold
Price Target: $15 → $26
Current: $28.21
Upside: n/a
Jul 21, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $34.94
Upside: n/a
Jun 11, 2025
Maintained: Buy
Price Target: $45
Current: $25.40
Upside: n/a
May 29, 2025
Maintained: Hold
Price Target: $20 → $18
Current: $39.25
Upside: n/a
Nov 7, 2024
Initiated Coverage: Buy
Price Target: $8
Current: $2.50
Upside: n/a
Sep 19, 2024
Upgraded: Buy
Price Target: $35
Current: $36.60
Upside: n/a
Sep 3, 2024
Maintained: Hold
Price Target: $8 → $6
Current: $3.63
Upside: n/a
Jul 17, 2024
Maintained: Hold
Price Target: $1
Current: $2.64
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: $2,275 → $70
Current: $19.90
Upside: n/a
Jul 13, 2023
Maintained: Buy
Price Target: $18
Current: $1.91
Upside: n/a
Feb 14, 2023
Rated: Hold
Price Target: $35 → $22
Current: $111.62
Upside: n/a